Table 2.
Oncogenic Drivers Identified and Targeted Treatments Received for Patients With Any and Full Genotyping
| Gene With Mutational or Structural Change |
Genotyping, No. (%) [95% CI] |
Patients Receiving Targeted Therapy No. (%)c |
|
|---|---|---|---|
| Any (n = 1007)a,b | Full (n = 733)b | ||
| Any gene(s) | 623 (62) [59-65] | 466 (64) [60-67] | 275 (44) |
|
| |||
| Singletonsd | |||
|
| |||
| KRAS | 245 (24) [22-27] | 182 (25) [22-28] | 22 (9) |
|
| |||
| EGFR (sensitizing)e | 175 (17) [15-20] | 122 (17) [14-20] | 146 (83) |
|
| |||
| exon19 del | 103 (10) [9-12] | 68 (9) [7-12] | |
|
| |||
| L858R | 64 (6) [5-8] | 47 (6) [5-9] | |
|
| |||
| G719X | 5 (0.5) [0.2-1] | 5 (0.7) [0.3-2] | |
|
| |||
| L861Q | 5 (0.5) [0.2-1] | 4 (0.5) [0.2-2] | |
|
| |||
| ALK (rearrangement) | 80 (8) [6-10] | 57 (8) [6-10] | 52 (65) |
|
| |||
| EGFR (other)f | 35 (4) [3-5] | 29 (4) [3-6] | 23 (66) |
|
| |||
| ERBB2 (formerly HER2) | 23 (2) [2-4] | 19 (3) [2-4] | 11 (48) |
|
| |||
| BRAF | 18 (2) [1-3] | 16 (2) [1.3-3.6] | 3 (17) |
|
| |||
| V600E | 14 (1) [0.8-2] | 12 (2) [0.9-3] | 2 (14) |
|
| |||
| Non-V600E | 4 (0.4) [0.1-1] | 4 (0.5) [0.2-2] | 1 (25) |
|
| |||
| PIK3CA | 7 (0.7) [0.3-2] | 6 (0.8) [0.3-2] | 0 |
|
| |||
| MET (amplification) | 6 (0.6) [0.2-1] | 5 (0.7) [0.3-2] | 3 (50) |
|
| |||
| NRAS | 5 (0.5) [0.2-1] | 5 (0.7) [0.3-2] | 0 |
|
| |||
| MEK1 | 2 (0.2) [0.03-1] | 1 (0.1) [0-1] | 0 |
|
| |||
| AKT1 | 0 [0-1] | 0 [0-1] | 0 |
|
| |||
| Doubletons | |||
|
| |||
| >1 gene | 27 (3) [2-4] | 24 (3) [2-5] | 15 (56) |
For percentages in this column, 1007 is used as the denominator. Because not all cases in this group were tested for all genes, percentages reflect rate of detection of mutation where nondetection is a combination of negative findings and no findings.
Any genotyping indicates 1 to 10 total genes assayed; full genotyping, 10 genes assayed.
Percent among cases with detected driver in any genotyping group.
Per-gene count (percent) of patients with mutations occurring in a single gene (singletons). Patients with oncogenic drivers in more than 1 gene (doubletons) are included as their own category. For detailed information on mutations occurring within doubletons, see eTable 5 in the Supplement.
The sum of counts for the 4 categories of EGFR (sensitizing) mutations differs from the patient-level count of total number of patients with EGFR (sensitizing) mutations due to 2 patients with the co-occurrence of 2 different sensitizing mutations in the same specimen.
Patients are counted in the EGFR (other) group based on a finding of any one or more mutations in EGFR other than exon 19 deletions, L858R, G719X, or L861Q, with or without co-occurrence in the same tumor specimen of 1 of these sensitizing mutations. See eTable 5 in the Supplement for a detailed count of co-occurring EGFR mutations.